116 related articles for article (PubMed ID: 11741599)
1. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor.
Wenzel J; Sanzenbacher R; Ghadimi M; Lewitzky M; Zhou Q; Kaplan DR; Kabelitz D; Feller SM; Janssen O
FEBS Lett; 2001 Dec; 509(2):255-62. PubMed ID: 11741599
[TBL] [Abstract][Full Text] [Related]
2. Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178).
Ghadimi MP; Sanzenbacher R; Thiede B; Wenzel J; Jing Q; Plomann M; Borkhardt A; Kabelitz D; Janssen O
FEBS Lett; 2002 May; 519(1-3):50-8. PubMed ID: 12023017
[TBL] [Abstract][Full Text] [Related]
3. Slowly getting a clue on CD95 ligand biology.
Linkermann A; Qian J; Janssen O
Biochem Pharmacol; 2003 Oct; 66(8):1417-26. PubMed ID: 14555216
[TBL] [Abstract][Full Text] [Related]
4. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.
Li-Weber M; Krammer PH
Semin Immunol; 2003 Jun; 15(3):145-57. PubMed ID: 14563113
[TBL] [Abstract][Full Text] [Related]
5. A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation.
Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH
Eur J Immunol; 1998 Aug; 28(8):2373-83. PubMed ID: 9710215
[TBL] [Abstract][Full Text] [Related]
6. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
7. CD95 ligand--death factor and costimulatory molecule?
Janssen O; Qian J; Linkermann A; Kabelitz D
Cell Death Differ; 2003 Nov; 10(11):1215-25. PubMed ID: 12894217
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.
Bernassola F; Scheuerpflug C; Herr I; Krammer PH; Debatin KM; Melino G
Cell Death Differ; 1999 Jul; 6(7):652-60. PubMed ID: 10453076
[TBL] [Abstract][Full Text] [Related]
9. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage.
Mariani SM; Krammer PH
Eur J Immunol; 1998 Mar; 28(3):973-82. PubMed ID: 9541592
[TBL] [Abstract][Full Text] [Related]
11. Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter.
Kirchhoff S; Sebens T; Baumann S; Krueger A; Zawatzky R; Li-Weber M; Meinl E; Neipel F; Fleckenstein B; Krammer PH
J Immunol; 2002 Feb; 168(3):1226-34. PubMed ID: 11801659
[TBL] [Abstract][Full Text] [Related]
12. Evidence for multiple CD95-CD95 ligand interactions in anteriorchamber-associated immune deviation induced by soluble protein antigen.
Kezuka T; Streilein JW
Immunology; 2000 Mar; 99(3):451-7. PubMed ID: 10712676
[TBL] [Abstract][Full Text] [Related]
13. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
14. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
15. The three-dimensional solution structure and dynamic properties of the human FADD death domain.
Berglund H; Olerenshaw D; Sankar A; Federwisch M; McDonald NQ; Driscoll PC
J Mol Biol; 2000 Sep; 302(1):171-88. PubMed ID: 10964568
[TBL] [Abstract][Full Text] [Related]
16. Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions.
Bajorath J
Proteins; 1999 Jun; 35(4):475-82. PubMed ID: 10382675
[TBL] [Abstract][Full Text] [Related]
17. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system.
Schlosser SF; Azzaroli F; Dao T; Hingorani R; Crispe IN; Boyer JL
Hepatology; 2000 Oct; 32(4 Pt 1):779-85. PubMed ID: 11003622
[TBL] [Abstract][Full Text] [Related]
18. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes.
Büssing A; Stein GM; Pfüller U; Schietzel M
Anticancer Res; 1999; 19(3A):1785-90. PubMed ID: 10470116
[TBL] [Abstract][Full Text] [Related]
19. Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system.
Mariani SM; Matiba B; Sparna T; Krammer PH
J Immunol Methods; 1996 Jun; 193(1):63-70. PubMed ID: 8690931
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
